Xov xwm
Txhim kho qhov ua tau zoo ntawm PROTAC: Kev Tshawb Fawb Txog Kev Tshawb Fawb
Ib txoj kev tshawb fawb tsis ntev los no hauv Nature Communications nthuav tawm cov kev nkag siab tseem ceeb rau hauv txoj hauv kev taw qhia qhov tseeb uas hloov kho cov txiaj ntsig ntawm cov phiaj xwm degradation siv PROTACs. Qhov kev tshawb pom no tuaj yeem ua rau txoj hauv kev rau kev kho mob zoo dua rau mob qog noj ntshav thiab lwm yam kab mob.
Txhawb Kev Noj Qab Haus Huv thiab Rov Qab Los: Kev Saib Xyuas Txhua Hnub rau Cov Neeg Mob Leukemia
Ua kom muaj kev nyab xeeb thiab xis nyob hauv kev kho mob rau cov neeg mob leukemia suav nrog kev saib xyuas txhua hnub, suav nrog kev huv huv ib puag ncig, kev tu tus kheej, khoom noj khoom haus, thiab kev tawm dag zog kom tsim nyog. Phau ntawv qhia no muab cov lus qhia tseem ceeb rau kev saib xyuas txhua hnub kom muaj txiaj ntsig zoo.
NS7CAR-T Cell Therapy Shows Promise for Treating R/R T-ALL/LBL
Ib txoj kev tshawb fawb tsis ntev los no qhia txog kev ua tau zoo thiab kev nyab xeeb ntawm NS7CAR-T cell therapy hauv kev kho mob rov qab los yog refractory T-cell mob lymphoblastic leukemia (R / R T-ALL) thiab T-cell lymphoblastic lymphoma (R / R T-LBL). Txoj kev kho no muab kev cia siab tshiab rau cov neeg mob uas muaj cov mob qog noj ntshav hnyav no.
Groundbreaking Results of CD7-Targeted CAR-T Therapy for T-ALL thiab T-LBL
Ib txoj kev tshawb fawb tsis ntev los no qhia txog cov txiaj ntsig tau zoo ntawm CD7-targeted chimeric antigen receptor (CAR) T cell therapy hauv kev kho cov neeg mob rov qab los yog refractory T-cell mob lymphoblastic leukemia (T-ALL) thiab T-cell lymphoblastic lymphoma (T-LBL).
Kev pab them nqi ntawm 2024 ASH Lub Rooj Sib Tham Txhua Xyoo thiab Kev Tshaj Tawm
Lub 66th Lub Rooj Sib Tham Txhua Xyoo ntawm American Society of Hematology (ASH) yuav muaj nyob rau lub Kaum Ob Hlis 7-10, 2024, ntawm San Diego Convention Center, qhia txog kev tshawb fawb thiab kev nce qib hauv hematology.
Tshaj tawm 2024 Lub Rooj Sib Tham Lu Daopei Hematology Txhua Xyoo thaum Lub Yim Hli
Lub 12th Lub Rooj Sib Tham Lu Daopei Hematology tau teem sijhawm rau lub Yim Hli 23-24, 2024, ntawm Beijing International Convention Center. Koom nrog peb rau kev sib tham txog kev pom thiab kev nce qib tshiab hauv hematology.
Kev Cia Siab Tshiab hauv Kev Kho Mob Cancer: TILs Therapy Emerges as the Next Frontier
Txawm hais tias muaj kev sib tw tsis tu ncua hauv kev lag luam thiab kev lag luam, CAR-T txoj kev kho cov kev txwv tau raug hais los ntawm kev cog lus tshiab: Tumor-Infiltrating Lymphocyte (TIL) therapy. Qhov kev tawg no tau tshaj tawm lub sijhawm tshiab hauv kev tawm tsam cov qog nqaij hlav.
Puas yog Cellular Therapies yav tom ntej ntawm autoimmune Disease?
Kev kho mob rau cov qog nqaij hlav kuj tseem tuaj yeem kho thiab rov kho lub cev tiv thaiv kab mob kom muab kev kho mob mus ntev lossis tej zaum txawm kho qee yam kab mob autoimmune.